DEF: Altimmune Seeks Shareholder OK for Stock, ESPP Boost

Altimmune, Inc. will hold its 2026 Annual Meeting to vote on director elections, auditor ratification, executive pay, and proposals to increase authorized common stock and expand its employee stock purchase plan.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on Thursday, April 16, 2026, at 8:30 a.m., Eastern Time.
• Stockholders will vote on the election of nine directors, each for a one-year term.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, will be put to a vote for ratification.
• An advisory vote on the compensation of the company's named executive officers will be held.
• A proposal to amend the company's certificate of incorporation to increase the authorized shares of common stock from 200,000,000 to 400,000,000 will be voted upon.
• An amendment to the Altimmune, Inc. 2019 Employee Stock Purchase Plan (ESPP) to increase the number of shares reserved from 403,500 to 1,108,827 will be presented for approval.
• Authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies will also be voted on.
• The company achieved approximately 97.5% of its target annual performance-based cash bonuses for named executive officers in 2025, driven by successful clinical trial progress and regulatory designations.
• Net loss for 2025 was $88,093 thousand, an improvement from $95,059 thousand in 2024.
• Total Shareholder Return (TSR) for 2025 was 21.95%, a decrease from 78.71% in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting strong clinical and regulatory progress for its lead asset, pemvidutide, and proactive corporate governance adjustments, despite a decrease in TSR.

Positives

• Successful completion of the IMPACT Phase 2b trial of pemvidutide in MASH with positive topline data, meeting one of the co-primary endpoints at 24 weeks and reinforcing potential at 48 weeks.
• Received Breakthrough Therapy Designation for pemvidutide in MASH from the FDA, which can expedite development and review.
• Received Fast Track designation for pemvidutide for the treatment of Alcohol Use Disorder (AUD) from the FDA.
• Successful enrollment in the RECLAIM Phase 2 trial evaluating pemvidutide in subjects with AUD and initiation of enrollment in the RESTORE Phase 2 trial for Alcohol-Associated Liver Disease (ALD).
• Net loss decreased from $95,059 thousand in 2024 to $88,093 thousand in 2025, indicating improved financial performance.
• Achieved 97.5% of target annual performance-based cash bonuses for named executive officers in 2025, reflecting strong operational execution against corporate objectives.
• Appointment of Jerome Durso as President and Chief Executive Officer, bringing over 30 years of life sciences leadership experience, including a successful rare liver disease franchise at Intercept Pharmaceuticals.
• Appointment of Wayne Pisano as lead independent director, enhancing independent oversight.

Negatives

• Total Shareholder Return (TSR) decreased significantly from 78.71% in 2024 to 21.95% in 2025.
• The proposed increase in authorized common stock from 200,000,000 to 400,000,000 shares could have a dilutive effect on earnings per share, book value per share, and the voting power and interest of current stockholders upon future issuances.
• The increase in authorized shares may be deemed to have potential anti-takeover effects, making a change in control more difficult.

Risks

• Future issuances of additional shares of common stock or securities convertible into common stock could have a dilutive effect on earnings per share, book value per share, and the voting power and interest of current stockholders.
• The availability of additional authorized shares could, under certain circumstances, discourage or make more difficult any efforts to obtain control of the company, potentially impacting shareholder value.
• Without an increase in authorized shares, the company may be constrained in its ability to raise capital in a timely fashion or at all, potentially hindering clinical programs, product commercialization, or other important business activities.
• Cybersecurity threats or incidents could materially affect the company's strategy, results of operations, or financial condition, despite the implementation of an Enterprise Risk Management (ERM) program and protective measures.

Future Outlook

The company is strategically progressing into late-stage biotechnology, with a primary focus on the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the company is exploring pemvidutide for other indications, including alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).

Management Comments

• The Board made the determination that Jerome Durso is the right person to lead the Company as it transitions to Phase 3.
• We believe that our named executive officer compensation program is designed to achieve its goal with its emphasis on long-term equity awards and performance-based compensation, in addition to short-term (annual) incentive awards, specifically cash incentives, which are intended to enable the Company to successfully motivate and reward its named executive officers.
• We believe that the 2019 ESPP is also a key recruiting and retention tool in a competitive market.

Industry Context

StockSavvy.ai notes that Altimmune's strategic focus on advancing pemvidutide into Phase 3 for MASH, alongside exploring AUD and ALD, aligns with a broader industry trend of biopharmaceutical companies targeting metabolic and liver diseases, which represent significant unmet medical needs and large market opportunities. The FDA's Breakthrough Therapy and Fast Track designations for pemvidutide underscore its potential and could accelerate its development compared to competitors in these complex therapeutic areas.

Comparison to Industry Standards

• Altimmune's executive compensation peer group is composed of U.S. publicly traded biotechnology or pharmaceutical companies with market capitalization between $100 million and $1 billion, lead asset clinical stage II or III, and 25-200 full-time employees. This selection criteria is a standard industry practice for benchmarking executive compensation in the biotech sector.
• The company's compensation philosophy, which emphasizes long-term equity awards and performance-based compensation, is consistent with common industry practices aimed at aligning executive interests with shareholder value creation in high-growth, R&D-intensive sectors.
• The 97.5% achievement of performance-based cash bonuses for named executive officers in 2025, driven by successful clinical trial outcomes and regulatory designations, indicates strong operational execution relative to internal targets, which is a positive signal for a clinical-stage biotech company.

Management Changes

Corporate Governance

Related Party Transactions

• Catherine Sohn entered into a consulting agreement with the company from January 15, 2025, through January 15, 2026. The Board determined this relationship did not impair her independence.

Stakeholder Impact

• Shareholders: Potential for dilution from the proposed increase in authorized shares, but also potential for future capital raises and strategic transactions. Opportunity to vote on key governance matters and executive compensation.
• Employees: Increased shares reserved for the 2019 Employee Stock Purchase Plan (ESPP) allows more employees to invest in the company, serving as a recruitment and retention tool. Executive compensation program aims to attract and retain high-caliber officers.
• Customers/Patients: Continued clinical development of pemvidutide for MASH, AUD, and ALD aims to bring new therapies to market, potentially addressing significant unmet medical needs.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on April 16, 2026, to vote on the proposed agenda items.
• Continue Phase 3 development of pemvidutide for MASH.
• Continue development of pemvidutide for Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD).
• File a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) within four business days after the Annual Meeting to publish final voting results.

Key Dates

Recommendation

The company demonstrates strong clinical and regulatory progress with its lead asset, pemvidutide, and has implemented proactive governance changes, including new leadership. However, the proposed significant increase in authorized shares, while enabling future capital raises, introduces potential dilution. The decrease in Total Shareholder Return (TSR) from 2024 to 2025 also warrants a cautious approach. A 'hold' recommendation allows investors to monitor the execution of Phase 3 trials and the impact of potential future share issuances before making further investment decisions.

Keywords

Altimmune, Biotechnology, Pharmaceuticals, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Stock Options, RSU, Employee Stock Purchase Plan, ESPP, Authorized Shares, Common Stock, Dilution, MASH, AUD, ALD, Pemvidutide, Clinical Trials, FDA, Breakthrough Therapy, Fast Track, Jerome Durso, Ernst & Young